No Data
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
PDF VersionNEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
Axsome Therapeutics (AXSM) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $97 to $190.
Express News | Axsome Therapeutics Inc : RBC Raises Target Price to $131 From $130
Axsome Therapeutics' Auvelity Shows Strong Market Penetration and Sales Growth Potential
Mizhuo's Top Picks in Healthcare for July
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Morgan Stanley analyst Vikram Purohit maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $115.According to TipRanks data, the analyst has a success rate of 2